San Diego, CA -- (SBWIRE) -- 11/10/2015 -- An investigation on behalf of shareholders in NASDAQ:HTWR shares was announced over possible securities laws violations by HeartWare International and certain of its directors and officers in connection certain financial statements.

Investors who purchased shares of HeartWare International Inc (NASDAQ:HTWR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of HeartWare International Inc (NASDAQ:HTWR) concerning whether a series of statements by HeartWare International regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

HeartWare International Inc reported that its annual Total Revenue rose from $110.92 million in 2012 to $278.42 million in 2014 and that its respective Net Loss declined from $87.72 million to $19.37 million.

On September 9, 2015, HeartWare International Inc disclosed that it had paused its MVAD clinical trial to address an MVAD controller manufacturing process issue. Then, on October 13, 2015, HeartWare International Inc announced that following the company's investigation of causes of reported adverse effects in certain clinical trial patients, HeartWare might not re-initiate enrollment in the MVAD clinical trial in November as it had previously planned. Shares of HeartWare International Inc (NASDAQ:HTWR) declined from $90.71 per share in late July 2015 to as low as $34.70 per share on October 14, 2015.

On November 9, 2015, NASDAQ:HTWR shares closed at $46.79 per share.

Those who purchased shares of HeartWare International Inc (NASDAQ:HTWR) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com